118 related articles for article (PubMed ID: 2096917)
1. Electrophilic analogues of daunorubicin and doxorubicin.
Rosik LO; Sweet F
Bioconjug Chem; 1990; 1(4):251-6. PubMed ID: 2096917
[TBL] [Abstract][Full Text] [Related]
2. Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.
Sweet F; Rosik LO; Sommers GM; Collins JL
Gynecol Oncol; 1989 Sep; 34(3):305-11. PubMed ID: 2788601
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian cancers specifically bind daunorubicin-OC-125 conjugate: an immunofluorescence study.
Dezsö B; Török I; Rosik LO; Sweet F
Gynecol Oncol; 1990 Oct; 39(1):60-4. PubMed ID: 2227573
[TBL] [Abstract][Full Text] [Related]
4. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE
J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of amino acid derivatives of daunorubicin and doxorubicin in suspension of renal proximal tubules.
Hjelle JT; Baurain R; Masquelier M; Trouet A
J Pharmacol Exp Ther; 1984 May; 229(2):372-80. PubMed ID: 6585548
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
7. Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.
Huybrechts M; Symann M; Trouet A
Cancer Res; 1979 Sep; 39(9):3738-43. PubMed ID: 476697
[TBL] [Abstract][Full Text] [Related]
8. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI
Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368
[TBL] [Abstract][Full Text] [Related]
9. New anthracycline glycosides obtained by the nitrous acid deamination of daunorubicin, doxorubicin and their configurational analogues.
Cassinelli G; Ballabio M; Arcamone F; Casazza AM; Podesta' A
J Antibiot (Tokyo); 1985 Jul; 38(7):856-67. PubMed ID: 3861603
[TBL] [Abstract][Full Text] [Related]
10. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
[TBL] [Abstract][Full Text] [Related]
11. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect.
Schlage P; Mezo G; Orbán E; Bosze S; Manea M
J Control Release; 2011 Dec; 156(2):170-8. PubMed ID: 21864594
[TBL] [Abstract][Full Text] [Related]
13. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline Efficacy in vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types.
Wiles ME; Bell C; Landfair D; Lynam E; Bendele RA
Drug Deliv; 1997; 4(4):255-62. PubMed ID: 26582444
[TBL] [Abstract][Full Text] [Related]
15. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.
Averbuch SD; Clawson RE; Bachur NR; Felsted RL
Cancer Chemother Pharmacol; 1986; 16(3):211-7. PubMed ID: 2421935
[TBL] [Abstract][Full Text] [Related]
17. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
18. Recognition of anthracycline binding domains in bovine serum albumin and design of a free fatty acid sensor protein.
Demant EJ; Sehested M
Biochim Biophys Acta; 1993 Feb; 1156(2):151-60. PubMed ID: 8427874
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
Zenebergh A; Baurain R; Trouet A
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):115-21. PubMed ID: 6537910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
